Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Instagram Outage Disrupts Thousands of U.S. Users 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
LONDON, March 22, 2016 -- APCER Life Sciences, the truly global provider of safety, medical, regulatory, and technology services, will be a major participant in the Drug Information Association’s 28th Annual EuroMeeting, taking place April 6-8, 2016, in Hamburg, Germany. The company will host a presentation in the Innovation Theatre and have a large presence in the exhibit hall of the Congress Center Hamburg.
“We are excited that we have reached the point in our company’s growth where we can support the DIA EuroMeeting at a significant level,” said Michael Britt, APCER Europe’s business unit leader and Global Head of Quality and Compliance. “The European clients that we have been serving since our founding helped us define our value proposition and build our firm into the global presence it is today.”
APCER’s presentation in the Innovation Theatre is titled “Redefining PV: From Pharmacovigilance to Patient Voice and Product Value.” It will explore how pharmacovigilance, when practiced with consistency and integrated tightly with medical affairs, can yield a rich source of real-world patient data that quantifies product value and demonstrates a competitive advantage for partnering and out-licensing deals, formulary decisions, and reimbursement rates.
APCER Life Sciences is active in the Drug Information Association around the world. In addition to the EuroMeeting, the company will be speaking at the DIA Innovations in Pharmacovigilance meeting in Mumbai, India, May 13-14, and at the 52nd DIA Annual Meeting in Philadelphia, Pennsylvania, USA, June 27-30. APCER is also exhibiting at the DIA Medical Affairs and Scientific Communications Annual Forum in Orlando, Florida, USA, this week.
About APCER Life Sciences
APCER Life Sciences is committed to improving health in partnership with its clients. It brings together safety, medical, regulatory, and technology resources from around the world to ensure that patients receive the safest, most effective therapies possible.
To learn how APCER Life Sciences works together for better health, please follow the company on Twitter, LinkedIn, and Facebook; visit www.apcerls.com; then contact APCER at one of their global offices.
Contact: Jill Notte Director, Global Marketing +1-609-436-4714
